| KUBEŠOVÁ, Blanka, Šárka PAVLOVÁ, Jitka MALČÍKOVÁ, Jitka KABÁTHOVÁ, Lenka RADOVÁ, Nikola TOM, Boris TICHÝ, Karla PLEVOVÁ, Barbara KANTOROVÁ, Kristýna FIEDOROVÁ, Jarmila KISSOVÁ, B. GISSLINGER, H. GISSLINGER, Jiří MAYER, Robert KRALOVICS, Šárka POSPÍŠILOVÁ a Michael DOUBEK. Low-Burden TP53 mutations occur in chronic phase of myeloproliferative neoplasms regardless of hydroxyurea administration, disease type and JAK2 status. In Blood (2016); s. 4284. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016). 2016. |
Další formáty:
BibTeX
LaTeX
RIS
@proceedings{1365995,
author = {Kubešová, Blanka and Pavlová, Šárka and Malčíková, Jitka and Kabáthová, Jitka and Radová, Lenka and Tom, Nikola and Tichý, Boris and Plevová, Karla and Kantorová, Barbara and Fiedorová, Kristýna and Kissová, Jarmila and Gisslinger, B. and Gisslinger, H. and Mayer, Jiří and Kralovics, Robert and Pospíšilová, Šárka and Doubek, Michael},
booktitle = {Blood (2016); s. 4284. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016)},
title = {Low-Burden TP53 mutations occur in chronic phase of myeloproliferative neoplasms regardless of hydroxyurea administration, disease type and JAK2 status},
year = {2016}
}
TY - CONF
ID - 1365995
AU - Kubešová, Blanka - Pavlová, Šárka - Malčíková, Jitka - Kabáthová, Jitka - Radová, Lenka - Tom, Nikola - Tichý, Boris - Plevová, Karla - Kantorová, Barbara - Fiedorová, Kristýna - Kissová, Jarmila - Gisslinger, B. - Gisslinger, H. - Mayer, Jiří - Kralovics, Robert - Pospíšilová, Šárka - Doubek, Michael
PY - 2016
TI - Low-Burden TP53 mutations occur in chronic phase of myeloproliferative neoplasms regardless of hydroxyurea administration, disease type and JAK2 status
ER -
KUBEŠOVÁ, Blanka, Šárka PAVLOVÁ, Jitka MALČÍKOVÁ, Jitka KABÁTHOVÁ, Lenka RADOVÁ, Nikola TOM, Boris TICHÝ, Karla PLEVOVÁ, Barbara KANTOROVÁ, Kristýna FIEDOROVÁ, Jarmila KISSOVÁ, B. GISSLINGER, H. GISSLINGER, Jiří MAYER, Robert KRALOVICS, Šárka POSPÍŠILOVÁ a Michael DOUBEK. Low-Burden TP53 mutations occur in chronic phase of myeloproliferative neoplasms regardless of hydroxyurea administration, disease type and JAK2 status. In \textit{Blood (2016); s. 4284. (58th ASH Annual Meeting and Exposition, San Diego, USA, prosinec 2016)}. 2016.
|
